CPRX Catalyst Pharma: Accounting Value per Share

Catalyst Pharmaceuticals (CPRX) - corporate logo

The Catalyst Pharmaceuticals (CPRX) price chart on the GURU.Markets platform reflects the dynamics of an asset whose production is fully outsourced to GMP-standard contractors. The business focuses on treating rare pathologies, ensuring revenue stability regardless of market cycles, with the current figure standing at 8.24. However, geopolitical tensions could disrupt the logistics of components from Asia, creating risks for supply chains.

Catalyst Pharma (CPRX) Equity per Share: for the period 07/04/2022 - 07/25/2026

catalystpharma.com - analytical breakdowns and key metrics (CPRX)

- price and consensus price forecast:
Price Chart Catalyst Pharmaceuticals Inc|CPRX - Fair Value Consensus
- market capitalization data:
Market Valuation Catalyst Pharmaceuticals, Inc.|CPRX - Business Value
- book capitalization data:
Net Assets per Single Share Catalyst Pharmaceuticals|CPRX - Accounting Capitalization|Market Capitalization to Book Value Ratio catalystpharma.com|CPRX - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Catalyst Pharmaceuticals|CPRX - Long-Term Debt to Capital|Short-Term Debt to Equity Catalyst Pharmaceuticals, Inc.|CPRX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Catalyst Pharmaceuticals, Inc.
Fundamental company valuation:Catalyst Pharmaceuticals Inc, CPRX
Manufactured products of Catalyst Pharmaceuticals, Inc.

The monopoly status of the drug Inertia ensures a steady capital inflow, which is reflected in the upward trend of the BVPS. This metric is calculated as the difference between total assets and liabilities, divided by the number of outstanding shares. The metric captures the actual value of equity available to shareholders. Growth in this value confirms resource preservation and reduces credit risks. For Catalyst Pharmaceuticals (CPRX), such a trend guarantees the financial stability of the business.

Competitors of Catalyst Pharmaceuticals (CPRX)

Net Assets per Single Share Biogen Corp (BIIB)|Neurocrine Corp (NBIX) - Accounting Value of a Share|Accounting Value per Share Regencell Bioscience|AXSM (axsome.com) - Equity per Share|Net Assets per Single Share ACADIA Pharmaceuticals Inc. (ACAD)|Equity per Share Xenon Pharmaceuticals Inc.|Viking Pharma - Book Value per Share|Net Asset Value per Share Supernus Corp SUPN|Accounting Value per Share DNLI (Denali Therapeutics)|harmonybiosciences.com - Book Value per Share|Net Assets per Single Share Biohaven (BHVN)|AMLX: Accounting Value of a Share|Net Assets per Single Share TRVI|Praxis Corp (PRAX) - Net Asset Value per Share|Book Value per Share AVXL|Accounting Value per Share ceribell.com|Book Value per Share PRTA|Book Value per Share alector.com ALEC|Accounting Value per Share Annexon Inc. (ANNX)|Book Price of a Share Omeros Corp OMER|Neurogene Inc. - Book Value per Share|ACIU: Book Value per Share|Voyager Therapeutics, Inc. (VYGR) - Net Assets per Single Share|Net Assets per Single Share Neumora|Accounting Value per Share SCLX (Scilex Holding Co.)|Net Asset Value per Share TVGN|ACOG (Alpha Cognition) - Net Assets per Single Share|Net Assets per Share Cognition Therapeutics Inc. CGTX|Accounting Value per Share Inhibikase Therapeutics, Inc. (IKT)|SAVA - Book Price of a Share|Accounting Value per Share Assertio Therapeutics (ASRT)|COYA: Accounting Value of a Share|Net Assets per Single Share vistagen.com (VTGN)|Ovid Therapeutics (OVID) - Share Book Value|ABOS - Book Value per Share|Accounting Value of a Share CervoMed, Inc.|Book Value per Share ATHE|Book Value per Share CLNN (clene.com)|Net Assets per Single Share PepGen|Jupiter Neurosciences, Inc. - Accounting Value of a Share|RLMD: Net Assets per Single Share|ANVS - Accounting Value per Share|GRCE: Book Value per Share|Firefly Neuro (AIFF) - Book Value per Share|Book Value per Share KLTO|Accounting Value per Share NeuroSense Therapeutics, Ltd.|Reviva Pharmaceuticals Holdings, Inc. - Book Value per Share|Net Asset Value per Share metaviatx.com MTVA|Accounting Value per Share NRXS (NeurAxis, Inc)|HSDT - Book Value per Share|Accounting Value per Share Passage Bio Corp PASG|NEUP - Book Price of a Share|Minerva Neurosciences, Inc. - Book Value per Share|Athira Pharma Inc (ATHA) - Net Assets per Share|Book Value per Share ADXN|Accounting Value per Share Alzamend|Book Value per Share CYCN|Book Value per Share PTIX (protagenic.com)|Net Assets per Single Share Pasithea Therapeutics Corp. KTTA|Cortigent Inc - Net Assets per Single Share|Net Assets per Single Share ATXI (Avenue Therapeutics, Inc)|BCLI - Net Assets per Share|CARA (Cara Therapeutics, Inc.) - Book Value per Share|CHRO (chromocell.com) - Accounting Value per Share|Net Assets per Single Share Eliem Therapeutics, Inc. ELYM|Share Book Value ITCI|Longboard Pharma (LBPH) - Net Assets per Single Share|Accounting Value of a Share Marinus Pharma MRNS|NKGN - Accounting Value per Share|neurobopharma.com - Equity per Share|Sage Therapeutics (SAGE) - Net Assets per Single Share|SNPX - Equity per Share|Book Value per Share TRVN|Net Asset Value per Share Vigil Neuroscience, Inc.|WENA (Anew Medical) - Accounting Value per Share|Book Value per Share CERE